

a' 66. A kit for preparing the vaccine of claim 38 comprising (i) the at least one porcine parvovirus antigen and (ii) the at least one porcine circovirus antigen, wherein (i) and (ii) are packaged separately.

Sub-B2 67. The kit of claim 66 wherein the porcine circovirus antigen comprises at least one porcine circovirus type II antigen.--

14 Please cancel claims 1-37, without prejudice, without admission, without surrender of subject matter, and without any estoppel as to equivalents.

REMARKS

Claims 38-67 are now pending. They parallel the claims allowed in the parent application. No new matter is added. By this Amendment, there is now 1 independent claim and 30 claims in total. The filing fee has been calculated accordingly. As to the sequence listing, it is stated that the sequence listing in this application is the same as in prior parent application Serial No. 09/347,594, filed September 13, 1999. It is respectfully requested that the U.S. PTO use the electronic version of the sequence listing in that prior application, making any necessary changes therein for this application, e.g., as to Serial Number and filing date; and, a copy of the hard copy of the sequence listing filed in that prior application is submitted herewith.

It is believed that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R. §1.821(f) and (g) are set forth below.

Pursuant to 37 C.F.R. §1.821(g), the undersigned attorney of record hereby states that this submission, filed in accordance with 37 C.F.R. §1.821(g), does not contain new matter.

Pursuant to 37 C.F.R. §1.821(f), the undersigned attorney hereby states that the content of the paper copy submitted herewith, and the computer readable copy of the Sequence listing submitted in U.S. Serial No. 09/347,594 in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

In view of the amendments, remarks and enclosures herewith, the application complies with the requirements for computer readable disclosure of the biological sequences under 37 C.F.R. §1.821-1.825.


Please charge any additional fees incurred by reason of this paper to Deposit Account No.
50-0320.

Early and favorable examination of the application, on the merits, is earnestly solicited.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By:



Thomas J. Kowalski

Reg. No. 32,147

Tel 212-588-0800

Fax 212-588-0500

Encs. - Abstract
- Sequence Listing

FOR FILING